LeMaitre Vascular expects to record a charge of approximately $1.1 million in Q3 2007 as a result of this transaction.
Forward-Looking Statements
This press release contains forward-looking statements within the
meaning of the U.S. Private Securities Litigation Reform Act of 1995.
Statements in this press release regarding the Company's business that are
not historical facts may be "forward-looking statements" that involve risks
and uncertainties. Specifically, statements regarding the Company's
financial guidance and its operational objectives, and the Company's
ability to hire a direct sales organization, attain higher gross margins
and develop closer relationships with Italian vascular surgeons, are
forward-looking statements involving risks and uncertainties.
Forward-looking statements are based on management's current, preliminary
expectations and are subject to risks and uncertainties that could cause
actual results to differ from the results predicted and include, but are
not limited to, the Company's ability to successfully retain Serom's
customer base for LeMaitre Vascular products, the Company's ability to
retain a material portion of Serom's sales agent network, the Company's
ability to expand its sales force in Italy, risks related to product demand
and market acceptance of the Company's products, the significant
competition the Company faces from other companies, technologies and
alternative medical procedures, the Company's ability to expand its product
offerings through internal development or acquisition, the Company's
ability to realize the anticipated benefits of its acquisitions, disruption
at the Company's single manufacturing facility, the Company's lack of
experience with and gene
'/>"/>
| SOURCE LeMaitre Vascular, Inc. Copyright©2007 PR Newswire. All rights reserved |